Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$LJPC $heff didn't know if you have seen this s-8 filed on 12/20/13.
http://bit.ly/1gripg8
$ONCS someone's dumping.
$ACHN $3.99 in @ 3.86 pm
LOL thanks for the mention. ;~)
$DARA senderos good question?
$CPRX
8:03 am Catalyst Pharma reports 'Positive' cardiac safety results of its Phase 3 product, Firdapse tablets; the study met the pre-specified primary endpoint (CPRX) : Co announced positive results from a study jointly funded with, and conducted by BioMarin Pharma (BMRN) to assess the cardiac safety of Firdapse tablets (amifampridine also known as 3,4-DAP). Firdapse is approved in the E.U., where it is marketed by BioMarin. Firdapse is also currently in Phase 3 development in the U.S. for Lambert-Eaton Myasthenic Syndrome (:LEMS) by Catalyst.
http://yhoo.it/1hvg7Ak
$CPRX
8:03 am Catalyst Pharma reports 'Positive' cardiac safety results of its Phase 3 product, Firdapse tablets; the study met the pre-specified primary endpoint (CPRX) : Co announced positive results from a study jointly funded with, and conducted by BioMarin Pharma (BMRN) to assess the cardiac safety of Firdapse tablets (amifampridine also known as 3,4-DAP). Firdapse is approved in the E.U., where it is marketed by BioMarin. Firdapse is also currently in Phase 3 development in the U.S. for Lambert-Eaton Myasthenic Syndrome (:LEMS) by Catalyst.
http://yhoo.it/1hvg7Ak
starcig I apologize if you took offense at my post. I too was just trying to be cute. Agreed on the redundancy here. I read all the posts here hoping to read some new info on $ONCS.
I understand that I just hope you're not here to bore me either. I'm sure you understand what I'm saying.
starcig I don't need to wash my eyes out with anything but apparently you do. I said I was long this stock. What part of that did you not understand?!
$ONCS I'm long this stock but you guys keep beating the same dead horse today over and over again. How about some new info. We know there will be 1700 attendees, we know 2014 milestones are coming, etc. I'm not trying to get on anyone's case but it gets old. Spice it up a bit, something new......
Catalyst Pharmac (CPRX) Class Action Suit Dismissed
Catalyst Pharmaceutical Partners, Inc. (Catalyst) (Nasdaq: CPRX) announced that on January 3, 2014, the previously reported stockholder class action lawsuit that had been filed against Catalyst and certain of its officers and directors was dismissed without prejudice. In the Court's order, the plaintiffs were granted leave to file an amended complaint within 20 days. Catalyst has no information as to whether any such amended complaint is planned by the plaintiffs. If an amended complaint is filed in the case, Catalyst intends to vigorously defend the amended lawsuit.
In October and November 2013, three securities class action lawsuits were filed against Catalyst and certain of its officers and directors in the U.S. District Court for the Southern District of Florida. The complaints, which were substantially identical, purported to state a claim for violation of federal securities laws on behalf of a class of those who purchased Catalyst's common stockbetween October 31, 2012 and October 18, 2013. Two of the lawsuits were voluntarily dismissed by the plaintiffs, and the last remaining case was the case dismissed on Friday.
http://bit.ly/19YGMR7
Catalyst Pharmac (CPRX) Class Action Suit Dismissed
Catalyst Pharmaceutical Partners, Inc. (Catalyst) (Nasdaq: CPRX) announced that on January 3, 2014, the previously reported stockholder class action lawsuit that had been filed against Catalyst and certain of its officers and directors was dismissed without prejudice. In the Court's order, the plaintiffs were granted leave to file an amended complaint within 20 days. Catalyst has no information as to whether any such amended complaint is planned by the plaintiffs. If an amended complaint is filed in the case, Catalyst intends to vigorously defend the amended lawsuit.
In October and November 2013, three securities class action lawsuits were filed against Catalyst and certain of its officers and directors in the U.S. District Court for the Southern District of Florida. The complaints, which were substantially identical, purported to state a claim for violation of federal securities laws on behalf of a class of those who purchased Catalyst's common stockbetween October 31, 2012 and October 18, 2013. Two of the lawsuits were voluntarily dismissed by the plaintiffs, and the last remaining case was the case dismissed on Friday.
http://bit.ly/19YGMR7
$CPRX AF the idiot's a fucking asshole!
$CPRX 2.30 Catalyst Pharmaceutical Partners Reports Successful Completion of Type B Breakthrough Therapy Meeting With FDA on Firdapse Tablets Development Program
First Meeting With FDA Since Receiving Breakthrough Therapy Designation for Firdapse
Anticipated Timeline for NDA Submission Remains on Track
CORAL GABLES, Fla., Jan. 6, 2014 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Catalyst) (CPRX), a specialty pharmaceutical company focused on developing safe and effective, approved medicines targeting orphan neuromuscular and neurological diseases, today announced the successful completion of a Type B meeting with the U.S. Food and Drug Administration (FDA) about Firdapse(TM) tablets (Amifampridine), its lead product being evaluated for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS).
Catalyst provided FDA with an update on the development program for Firdapse, which received Breakthrough Therapy designation from the FDA in August 2013. The Company also confirmed with FDA the clinical, nonclinical, and chemistry and manufacturing controls requirements that FDA will require to approve a New Drug Application (NDA) for Firdapse.
"Catalyst remains committed to completing our late-stage clinical trial of Firdapse as expeditiously as possible and working with the FDA to provide a complete NDA filing," said Patrick McEnany, President and CEO of Catalyst. "We believe that data obtained to date demonstrate the clinical value and benefit of Firdapse for LEMS patients, who today have no safe and effective, approved drug to treat their disease."
This Type B meeting with the FDA was Catalyst's first meeting as the sponsor of the IND for Firdapse. Catalyst will file rolling submissions of the NDA modules as completed in anticipation of receiving a priority review of its NDA for Firdapse.
The Company provided a briefing package to the FDA that described all completed, in-progress, and planned preclinical studies, clinical studies, and drug manufacturing activities. This package included summaries of 54 preclinical studies, six clinical studies, and information related to drug manufacturing (the clinical supplies and the to-be marketed commercial product). The FDA concurred that the Company's completed, in-progress, and planned development activities represented a nearly complete package of information that would be needed for a complete NDA.
Catalyst also will submit data from additional in-vitro preclinical studies. Based on the discussions at this meeting and based on past communications and meetings with the FDA about Firdapse, all of these studies and remaining development activities constitute information needed to file a complete NDA and seek approval for Firdapse. The Company does not anticipate that these additional studies will impact the NDA filing timeline or materially add to its forecast of the aggregate development costs for Firdapse.
The Company and FDA also discussed the acceptability of the primary and secondary endpoints specified in the protocol for the ongoing Phase 3 trial. FDA requested a slight modification in the analyses to be conducted for the endpoints, which the Company believes will not require any changes in the data being collected or the number of patients needed to complete enrollment.
Update on Phase 3 Clinical Trial Status
The Company anticipates meeting previously disclosed timelines for submission and approval of an NDA for Firdapse for the treatment of LEMS.
In order to accelerate the enrollment in this clinical trial, over the last few months the Company has expanded the on-going clinical trial that was initiated by BioMarin Pharmaceutical, Inc. (BMRN), to include many more sites internationally. The initiation of these clinical trial sites in numerous different countries has presented challenging logistical, contractual and regulatory issues that are nearing closure. These issues included site identification followed by numerous IRB/ethics committee filings, contracts, clinical trial applications, translations, IRB approvals, multilingual drug labeling, and other multinational issues.
There are currently 22 active sites with a sufficient number of already identified LEMS patients to complete enrollment of the trial, based on the screening, enrollment, and randomization success metrics achieved to date. As a result, the Company expects to complete screening and enrollment of the clinical trial during this quarter and to report top line data from the trial in the third quarter of this year.
http://yhoo.it/1hqrucy
$MSTX .55 8:01 am Mast Therapeutics announces positive data in model for heart failure; statistically significant improvement in key parameters of heart function, including left ventricular ejection fraction and cardiac output (MSTX) :
Co announced that, in a placebo-controlled, nonclinical model of chronic heart failure, MST-188 demonstrated a statistically significant improvement in numerous parameters of heart function, including left ventricular ejection fraction and end-systolic volume, stroke volume and cardiac output. Notably, a single two-hour infusion of MST-188 resulted in improvements that were significant immediately (at the end of MST-188 administration) and remained significant at one week (and, in some cases, at two weeks) after MST-188 administration.
The objective of the study was to determine the effect of acute intravenous administration of MST-188 on left ventricular systolic and diastolic cardiac function in a model of chronic heart failure produced by multiple sequential intracoronary microembolizations. A single dose of MST-188 (low or high dose) or placebo was administered over 2 hours. Hemodynamic, ventriculographic, echocardiographic and electrocardiographic measurements were taken at baseline (prior to study drug administration) and at the following time-points after the start of study drug administration: 2 hours (end of administration), 24 hours, 1 week and 2 weeks. Peripheral venous blood samples were obtained at the same time-points. The improvements described above were calculated as the difference between baseline and mean values of each study group at each time-point using a one-way analysis of variance, with p
http://yhoo.it/1gAPua2
$ONCS.... ero thanks for the clarification. Some boards you just don't know.
$ONCS camk, on this board a lot of talk about MM manipulation. But once the stock starts moving up this board gets real quiet until profits are being taken then as it moves down the MM manipulation talk starts again. And these same people load up. They keep the cycle going. LOL
$CHTP $3.74...I picked up some cheapies this morning around the lows.
Happy New Year to all at $heff's $tation. Let's kill it next year. Thanks $heff for all your DD and sharing.
$LJPC....I've had shares of this for 3 years.
$DARA yes it is. I'm in @ .54 looking for more @ lower price.
Take it to the correct board!
Wrong board. $DARA only.
It's more fun growing it.
Wishing All A Merry Christmas.
04:15 PM DARA Biosciences (DARA) Files $12.5M Common Shelf
http://www.streetinsider.com/
OT: Is it a 1/2 day market tomorrow?
Thanks bra1. I'm hoping to buy some back at a lower price. Took such a beating in the last month that I'm locking them profits in while they're there.
$POZN
"I was told it was for SH's of record on 12/30 with payment in January."
This is correct because of the 25% rule.
POZEN Inc. (POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced that the ex-dividend date for POZEN’s previously announced $1.75 special cash distribution is December 31, 2013. On November 21, 2013 POZEN announced that its Board of Directors had declared a special cash distribution of $1.75 per share payable to stockholders of record holding outstanding shares of POZEN’s common stock as of the close of business on December 11, 2013, with an expected payment date of December 30, 2013. Because the special cash distribution exceeded 25% of the value of POZEN’s common stock at the time of declaration, in accordance with Financial Industry Regulatory Authority Rule 11140, NASDAQ has determined that the ex-dividend date for this special cash distribution will be December 31, 2013, the first business day following the payable date. As a result, shares of POZEN’s common stock issued and outstanding on December 11, 2013 shall continue to trade with the right to receive the special cash distribution through the expected payment date of December 30, 2013. Please consult with your broker, legal or financial advisors as to any questions concerning the impact of the December 31, 2013 ex-dividend date.
http://yhoo.it/1kmXwWw
$POZN Pozen will pay $1.75 special dividend in December
Pozen says it will return cash to shareholders with special dividend of $1.75 in December.
CHAPEL HILL, N.C. (AP) -- Drugmaker Pozen said Thursday it will pay a special cash dividend of $1.75 as it has a "surplus of corporate cash."
Shares jumped 82 cents, or 12 percent, to $7.62 in after-hours trading.
Pozen Inc. said it will pay the dividend on Dec. 30 to shareholders of record as of Dec. 11.
http://yhoo.it/19VDFpQ
$POZN some people are buying for the $1.75 per share dividend at end of month.
OT: Click on microsoft icon in systray then accessories then snipping tool. Use snipping tool to crop the part you want in Ameritrade for screenshot. Name and save to desktop. Go to Ihub> settings> My Pictures> choose file to upload from your desktop and upload. Copy file from embed and paste in message.
OT: cabos do you use a pc or mac?